Galena Biopharma Announces Results From NeuVax Phase 1/2 Trials

Galena Biopharma

, a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, presented data from the completed SN-33 Trial and final results from the Phase 1/2 trials of NeuVax™ (nelipepimut-S or E75) at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The event is being held December 4-8, 2012 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. "New treatment options are needed to address unmet medical needs for breast cancer patients with HER2 low-to-intermediate expression or IHC